Denali Therapeutics Inc. (DNLI)
DNLI Stock Price Chart
Explore Denali Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze DNLI price movements and trends.
DNLI Company Profile
Discover essential business fundamentals and corporate details for Denali Therapeutics Inc. (DNLI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Dec 2017
Employees
443.00
CEO
Ryan J. Watts
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
DNLI Financial Timeline
Browse a chronological timeline of Denali Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.76, while revenue estimate is $1.00M.
Earnings released on 11 Aug 2025
EPS came in at -$0.72 surpassing the estimated -$0.74 by +2.70%.
Earnings released on 6 May 2025
EPS came in at -$0.78 falling short of the estimated -$0.71 by -9.86%.
Earnings released on 27 Feb 2025
EPS came in at -$0.67 surpassing the estimated -$0.75 by +10.67%.
Earnings released on 6 Nov 2024
EPS came in at -$0.63 falling short of the estimated -$0.60 by -5.00%.
Earnings released on 1 Aug 2024
EPS came in at -$0.59 surpassing the estimated -$0.68 by +13.24%.
Earnings released on 7 May 2024
EPS came in at -$0.68 falling short of the estimated -$0.67 by -1.49%.
Earnings released on 27 Feb 2024
EPS came in at -$0.86 falling short of the estimated -$0.82 by -4.88%, while revenue for the quarter reached -$305.04M , missing expectations by -3.75K%.
Earnings released on 7 Nov 2023
EPS came in at -$0.72 surpassing the estimated -$0.83 by +13.25%, while revenue for the quarter reached $1.27M , missing expectations by -85.83%.
Earnings released on 8 Aug 2023
EPS came in at $1.30 surpassing the estimated -$0.68 by +291.18%, while revenue for the quarter reached $294.12M , beating expectations by +2.09K%.
Earnings released on 8 May 2023
EPS came in at -$0.80 falling short of the estimated -$0.71 by -12.68%, while revenue for the quarter reached $35.14M , beating expectations by +22.34%.
Earnings released on 27 Feb 2023
EPS came in at -$0.75 surpassing the estimated -$0.78 by +3.85%, while revenue for the quarter reached $10.28M , missing expectations by -21.60%.
Earnings released on 3 Nov 2022
EPS came in at -$0.84 falling short of the estimated -$0.83 by -1.20%, while revenue for the quarter reached $3.56M , missing expectations by -79.09%.
Earnings released on 8 Aug 2022
EPS came in at -$0.48 surpassing the estimated -$0.52 by +7.69%, while revenue for the quarter reached $52.48M , beating expectations by +17.52%.
Earnings released on 5 May 2022
EPS came in at -$0.53 falling short of the estimated -$0.47 by -12.77%, while revenue for the quarter reached $42.14M , beating expectations by +26.32%.
Earnings released on 28 Feb 2022
EPS came in at -$0.62 falling short of the estimated -$0.41 by -51.22%, while revenue for the quarter reached $12.51M , missing expectations by -72.08%.
Earnings released on 4 Nov 2021
EPS came in at -$0.69 falling short of the estimated -$0.51 by -35.29%, while revenue for the quarter reached $5.29M , missing expectations by -83.50%.
Earnings released on 4 Aug 2021
EPS came in at -$0.50 falling short of the estimated -$0.37 by -35.14%, while revenue for the quarter reached $22.94M , meeting expectations.
Earnings released on 3 May 2021
EPS came in at -$0.58 falling short of the estimated -$0.37 by -56.76%, while revenue for the quarter reached $7.92M , beating expectations by +37.37%.
Earnings released on 25 Feb 2021
EPS came in at $1.91 surpassing the estimated $0.01 by +24.45K%, while revenue for the quarter reached $316.82M , beating expectations by +305.08%.
Earnings released on 5 Nov 2020
EPS came in at -$0.54 falling short of the estimated $3.57 by -115.13%, while revenue for the quarter reached $9.39M , missing expectations by -81.88%.
DNLI Stock Performance
Access detailed DNLI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.